Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren

Msd3.0

Methasterone (Superdrol) – Forschung

Überwiegend Mechanismus / Beobachtung

6 begutachtete Studien

Was die Evidenz sagt

Überwiegend Mechanismus / Beobachtung

Die meisten Studien zu Methasterone (Superdrol) sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.

Die meiste Evidenz stammt aus gemischt-qualitativen Studien, veröffentlicht 2006–2020.

Basierend auf 6 Studien

Konfidenz

Geringe Konfidenz

Nach Outcome

Safety profile
Überwiegend Mechanismus / Beobachtung6 Studien
Cholestatic liver injury
Überwiegend Mechanismus / Beobachtung4 Studien
Renal injury
Überwiegend Mechanismus / Beobachtung3 Studien
Androgenic anabolism (unverified)Ein Designer-Oralsteroid ("Superdrol") mit androgener Muskelanabolik (in Studien unbelegt), aber schwerer cholestatischer Leberschädigung, Nierenschädigung und HDL-Einbruch. Ein kontrollierter Wirkstoff. · Nicht etabliert (keine Wirksamkeitsstudien am Menschen)
Überwiegend Mechanismus / Beobachtung3 Studien

Ältere Forschungsbasis

Neueste Studie von 2020

200620132020

1Fallstudie2008

Methasteron use can result in severe hepatotoxicity. Liver failure can worsen after initial presentation, especially within 2 weeks.

Shah NL, Zacharias I, Khettry U, Afdhal N, Gordon FD. · Clinical gastroenterology and hepatology (2008)

Clinicopathologic case series of five men who developed cholestatic liver injury after using methasteron (Superdrol), with clinical course, laboratory data and liver histopathology
All presented with cholestatic hepatitis (jaundice, pruritus, marked hyperbilirubinemia); biopsies showed bland intrahepatic/canalicular cholestasis characteristic of 17α-alkylated AAS
Critically, liver failure could WORSEN after presentation — especially within the first two weeks after stopping the drug — a dangerous, counterintuitive course

Quelle ansehen

2Fallstudie2009

Severe cholestasis and renal failure associated with the use of the designer steroid Superdrol (methasteron).

Nasr J, Ahmad J. · Digestive diseases and sciences (2009)

Case report with literature review of a patient who developed severe cholestasis AND renal failure after using the designer steroid Superdrol (methasteron)
Captures the liver-plus-kidney pattern — severe cholestatic injury accompanied by renal dysfunction (bile-cast nephropathy can follow severe cholestasis)
Reviews the emerging literature on Superdrol/methasteron hepatotoxicity, reinforcing the 17α-alkylated-AAS cholestasis signal

Quelle ansehen

3Fallstudie2020

Liver biopsies showed 'bland' canalicular cholestasis ... a high proportion of patients developed associated kidney injury, and peak bilirubin levels were very high.

Abeles RD, Foxton M, Khan S, Goldin R, Smith B, Thursz MR, Verma S. · BMJ open gastroenterology (2020)

Two RUCAM-scored cases of anabolic-androgenic-steroid-induced liver injury plus a comprehensive literature review of AAS hepatotoxicity, the class to which methasterone belongs
Liver biopsies showed the bland canalicular cholestasis characteristic of 17α-alkylated AAS, with very high peak bilirubin
A high proportion of patients developed associated kidney injury — reinforcing the liver-plus-kidney pattern seen with Superdrol/methasteron

Quelle ansehen

4Fallstudie2006

Cholestatic jaundice and IgA nephropathy induced by OTC muscle building agent superdrol.

Jasiurkowski B, Raj J, Wisinger D, Carlson R, Zou L, Nadir A. · The American journal of gastroenterology (2006)

Case report of a young man who developed cholestatic jaundice together with IgA nephropathy after using the over-the-counter 'muscle building' agent superdrol (methasterone)
Documents combined hepatic and renal injury from an illicitly-marketed OTC 'prohormone' supplement — hepatic cholestasis plus renal disease
Authors emphasize that misleading supplement labeling creates false confidence in safety, with no clinical evidence of utility or safety

Quelle ansehen

5Tierstudie2011

Several metabolites, including a 3-keto reduced metabolite and numerous hydroxylated metabolites, were identified for methasterone in the chimeric mouse model with humanized liver.

Lootens L, Meuleman P, Leroux-Roels G, Van Eenoo P. · The Journal of steroid biochemistry and molecular biology (2011)

Characterized the metabolism of methasterone (and the designer steroids promagnon and methylclostebol) using uPA+/+-SCID chimeric mice with a humanized liver, for anti-doping detection purposes
Identified methasterone's phase I metabolites (3-keto-reduced and hydroxylated species) relevant to forensic urine detection of its illicit use
Part of the dominant non-clinical literature — characterizing the drug for DETECTION, not demonstrating any human benefit

Quelle ansehen

6In vitro2009

Common 3alpha-hydroxy (major) and 3beta-hydroxy reduced metabolites were identified for drostanolone and 17-methyldrostanolone using cryopreserved human hepatocytes.

Gauthier J, Goudreault D, Poirier D, Ayotte C. · Steroids (2009)

Identified the metabolites of 17-methyldrostanolone (methasterone/methyldrostanolone) and drostanolone produced by cryopreserved human hepatocytes, an in-vitro hepatic system
Characterized the 3α- and 3β-reduced (hydroxylated) metabolites used to detect methyldrostanolone in anti-doping testing
Confirms that methasterone is hepatically metabolized and tracked as a designer-steroid doping agent — detection science, not human benefit

Quelle ansehen

In der Forschungsbibliothek ansehen

Methasterone (Superdrol) – Forschung

Überwiegend Mechanismus / Beobachtung

Methasteron-associated cholestatic liver injury: clinicopathologic findings in 5 cases.

Severe cholestasis and renal failure associated with the use of the designer steroid Superdrol (methasteron): a case report and literature review.

Androgenic anabolic steroid-induced liver injury: two case reports assessed for causality by the updated Roussel Uclaf Causality Assessment Method (RUCAM) score and a comprehensive review of the literature.

Cholestatic jaundice and IgA nephropathy induced by OTC muscle building agent superdrol.

Metabolic studies with promagnon, methylclostebol and methasterone in the uPA+/+-SCID chimeric mice.

Identification of drostanolone and 17-methyldrostanolone metabolites produced by cryopreserved human hepatocytes.